International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force

Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer

Nancy U. Lin, Christoph Thomssen, Fatima Cardoso, David Cameron, Tanja Cufer, Lesley Fallowfield, Prudence A. Francis, Stella Kyriakides, Olivia Pagani, Elzbieta Senkus, Alberto Costa, Eric P. Winer

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

In clinical practice, the surveillance and follow-up of patients with breast cancer (BC) is quite variable. At the 7th European Breast Cancer Conference, the ESO-MBC Task Force convened a series of lectures, followed by open debate, on the use of physical examination, imaging, and laboratory tests in patients with early-stage BC, and for restaging evaluations and follow-up among patients with MBC. Based on the available data, the Task Force recommends against intensive, routine radiologic or blood-based surveillance (with the exception of mammography) in patients with early-stage BC. As systemic therapies for MBC continue to improve, this question might be re-visited in the context of a carefully controlled clinical trial in specific BC subtypes. For patients with MBC, response to therapy should generally be assessed 2-3 months after initiation of treatment, and thereafter every 2-4 months for endocrine therapy or every 2-4 cycles for chemotherapy, depending on the dynamics of the disease, the location and extent of metastatic involvement, and type of treatment. Additional testing should be performed irrespective of the planned intervals if progression of disease is suspected (e.g. in the case of specific symptoms). Use of tumor markers is not recommended for surveillance of early-stage patients, but may be helpful in monitoring response to therapy in patients with metastatic disease. However, change in tumor markers alone should not be used for decision-making. Moving forward, enhanced efforts to document quality of life over time should be made in order to more fully evaluate the risk/benefit ratio of available options.

Original languageEnglish
Pages (from-to)203-210
Number of pages8
JournalBreast
Volume22
Issue number3
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Advisory Committees
Guidelines
Breast Neoplasms
Tumor Biomarkers
Therapeutics
Controlled Clinical Trials
Mammography
Physical Examination
Disease Progression
Decision Making
Odds Ratio
Quality of Life
Drug Therapy

Keywords

  • ABC
  • Breast cancer
  • Evaluation
  • Follow-up
  • Guidelines
  • Staging
  • Surveillance

ASJC Scopus subject areas

  • Surgery

Cite this

International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force : Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. / Lin, Nancy U.; Thomssen, Christoph; Cardoso, Fatima; Cameron, David; Cufer, Tanja; Fallowfield, Lesley; Francis, Prudence A.; Kyriakides, Stella; Pagani, Olivia; Senkus, Elzbieta; Costa, Alberto; Winer, Eric P.

In: Breast, Vol. 22, No. 3, 06.2013, p. 203-210.

Research output: Contribution to journalArticle

Lin, Nancy U. ; Thomssen, Christoph ; Cardoso, Fatima ; Cameron, David ; Cufer, Tanja ; Fallowfield, Lesley ; Francis, Prudence A. ; Kyriakides, Stella ; Pagani, Olivia ; Senkus, Elzbieta ; Costa, Alberto ; Winer, Eric P. / International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force : Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. In: Breast. 2013 ; Vol. 22, No. 3. pp. 203-210.
@article{8ccc66e8fac74929a7eb05f0cfae6a70,
title = "International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer",
abstract = "In clinical practice, the surveillance and follow-up of patients with breast cancer (BC) is quite variable. At the 7th European Breast Cancer Conference, the ESO-MBC Task Force convened a series of lectures, followed by open debate, on the use of physical examination, imaging, and laboratory tests in patients with early-stage BC, and for restaging evaluations and follow-up among patients with MBC. Based on the available data, the Task Force recommends against intensive, routine radiologic or blood-based surveillance (with the exception of mammography) in patients with early-stage BC. As systemic therapies for MBC continue to improve, this question might be re-visited in the context of a carefully controlled clinical trial in specific BC subtypes. For patients with MBC, response to therapy should generally be assessed 2-3 months after initiation of treatment, and thereafter every 2-4 months for endocrine therapy or every 2-4 cycles for chemotherapy, depending on the dynamics of the disease, the location and extent of metastatic involvement, and type of treatment. Additional testing should be performed irrespective of the planned intervals if progression of disease is suspected (e.g. in the case of specific symptoms). Use of tumor markers is not recommended for surveillance of early-stage patients, but may be helpful in monitoring response to therapy in patients with metastatic disease. However, change in tumor markers alone should not be used for decision-making. Moving forward, enhanced efforts to document quality of life over time should be made in order to more fully evaluate the risk/benefit ratio of available options.",
keywords = "ABC, Breast cancer, Evaluation, Follow-up, Guidelines, Staging, Surveillance",
author = "Lin, {Nancy U.} and Christoph Thomssen and Fatima Cardoso and David Cameron and Tanja Cufer and Lesley Fallowfield and Francis, {Prudence A.} and Stella Kyriakides and Olivia Pagani and Elzbieta Senkus and Alberto Costa and Winer, {Eric P.}",
year = "2013",
month = "6",
doi = "10.1016/j.breast.2013.03.006",
language = "English",
volume = "22",
pages = "203--210",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force

T2 - Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer

AU - Lin, Nancy U.

AU - Thomssen, Christoph

AU - Cardoso, Fatima

AU - Cameron, David

AU - Cufer, Tanja

AU - Fallowfield, Lesley

AU - Francis, Prudence A.

AU - Kyriakides, Stella

AU - Pagani, Olivia

AU - Senkus, Elzbieta

AU - Costa, Alberto

AU - Winer, Eric P.

PY - 2013/6

Y1 - 2013/6

N2 - In clinical practice, the surveillance and follow-up of patients with breast cancer (BC) is quite variable. At the 7th European Breast Cancer Conference, the ESO-MBC Task Force convened a series of lectures, followed by open debate, on the use of physical examination, imaging, and laboratory tests in patients with early-stage BC, and for restaging evaluations and follow-up among patients with MBC. Based on the available data, the Task Force recommends against intensive, routine radiologic or blood-based surveillance (with the exception of mammography) in patients with early-stage BC. As systemic therapies for MBC continue to improve, this question might be re-visited in the context of a carefully controlled clinical trial in specific BC subtypes. For patients with MBC, response to therapy should generally be assessed 2-3 months after initiation of treatment, and thereafter every 2-4 months for endocrine therapy or every 2-4 cycles for chemotherapy, depending on the dynamics of the disease, the location and extent of metastatic involvement, and type of treatment. Additional testing should be performed irrespective of the planned intervals if progression of disease is suspected (e.g. in the case of specific symptoms). Use of tumor markers is not recommended for surveillance of early-stage patients, but may be helpful in monitoring response to therapy in patients with metastatic disease. However, change in tumor markers alone should not be used for decision-making. Moving forward, enhanced efforts to document quality of life over time should be made in order to more fully evaluate the risk/benefit ratio of available options.

AB - In clinical practice, the surveillance and follow-up of patients with breast cancer (BC) is quite variable. At the 7th European Breast Cancer Conference, the ESO-MBC Task Force convened a series of lectures, followed by open debate, on the use of physical examination, imaging, and laboratory tests in patients with early-stage BC, and for restaging evaluations and follow-up among patients with MBC. Based on the available data, the Task Force recommends against intensive, routine radiologic or blood-based surveillance (with the exception of mammography) in patients with early-stage BC. As systemic therapies for MBC continue to improve, this question might be re-visited in the context of a carefully controlled clinical trial in specific BC subtypes. For patients with MBC, response to therapy should generally be assessed 2-3 months after initiation of treatment, and thereafter every 2-4 months for endocrine therapy or every 2-4 cycles for chemotherapy, depending on the dynamics of the disease, the location and extent of metastatic involvement, and type of treatment. Additional testing should be performed irrespective of the planned intervals if progression of disease is suspected (e.g. in the case of specific symptoms). Use of tumor markers is not recommended for surveillance of early-stage patients, but may be helpful in monitoring response to therapy in patients with metastatic disease. However, change in tumor markers alone should not be used for decision-making. Moving forward, enhanced efforts to document quality of life over time should be made in order to more fully evaluate the risk/benefit ratio of available options.

KW - ABC

KW - Breast cancer

KW - Evaluation

KW - Follow-up

KW - Guidelines

KW - Staging

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=84877147107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877147107&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2013.03.006

DO - 10.1016/j.breast.2013.03.006

M3 - Article

VL - 22

SP - 203

EP - 210

JO - Breast

JF - Breast

SN - 0960-9776

IS - 3

ER -